Systemic Treatments for Metastatic Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Old Certainties and New Frontiers

Systemic Treatments for Metastatic Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Old Certainties and New Frontiers

Epidermal growth factor receptor 2 (EGFR2, also known as HER2) overexpression and/or amplification confers a more aggressive clinical behavior but also represents a therapeutic opportunity for targeted therapies in breast cancer (BC). Over the last 2 decades, the prognosis of HER2-positive metastati...

Descripció completa

Dades bibliogràfiques
Autors principals: Alessandro Rizzo MD, Antonio Cusmai MD, Raffaella Massafra PhD, Samantha Bove PhD, Maria Colomba Comes PhD, Annarita Fanizzi PhD, Gennaro Gadaleta-Caldarola MD, Donato Oreste MD, Alfredo Zito MD, Francesco Giotta MD, Vito Lorusso MD, Gennaro Palmiotti MD
Format: Article
Idioma:English
Publicat: SAGE Publishing 2022-05-01
Col·lecció:Cancer Control
Accés en línia:https://doi.org/10.1177/10732748221106267

Internet

https://doi.org/10.1177/10732748221106267

Ítems similars